Inhibitor ribonukleotidne reduktaze

Inhibitori ribonukleotidne reduktaze su familija antikancerni lekovi koji ometaju rast ćelija tumora blokiranjem formiranja dezoksiribonukleotida (gradivnih blokova DNK).

Primeri
  • moteksafin gadolinijum.[1]
  • hidroksiureja[2]
  • fludarabin, kladribin, gemcitabin, tezacitabin, i triapin[3]
  • galijum maltolat, galijum nitrat[4]

Reference

  1. Zahedi Avval F, Berndt C, Pramanik A, Holmgren A (January 2009). „Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd)”. Biochem. Biophys. Res. Commun. 379 (3): 775–9. DOI:10.1016/j.bbrc.2008.12.128. PMID 19121624. 
  2. Mayhew CN, Phillips JD, Cibull ML, Elford HL, Gallicchio VS (September 2002). „Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea”. Antivir. Chem. Chemother. 13 (5): 305–14. PMID 12630679. 
  3. Tsimberidou AM, Alvarado Y, Giles FJ (August 2002). „Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies”. Expert Rev Anticancer Ther 2 (4): 437–48. DOI:10.1586/14737140.2.4.437. PMID 12647987. 
  4. Bernstein LR (1998). „Mechanisms of therapeutic activity for gallium”. Pharmacol. Rev. 50 (4): 665–682. PMID 9860806. Arhivirano iz originala na datum 2007-02-26. Pristupljeno 2014-07-08. 

Vidi još

  • Ribonukleozid-difosfat reduktaza

Vanjske veze

  • Ribonucleotide reductase inhibitor entry in the public domain NCI Dictionary of Cancer Terms
  • p
  • r
  • u
Intracelularni hemoterapijski lekovi/Antineoplastični lekovi (L01)
SP/MI
(M faza)
Blokiranje formiranja microtubule
Blokiranje rasformiranja microtubule
Inhibitori
DNK replikacije
DNA prekursori/
antimetaboliti
(S faza)
inhibitor ribonukleotidne reduktaze (Hidroksikarbamid)
II+Interkalacija
Interkalacija
Fotosensitizeri/PDTDrugi
FI (Tipifarnib)  • CDK inhibitori (Alvocidib, Seliciklib) • PrI (Bortezomib) • PhI (Anagrelid) • IMPDI (Tiazofurin) • LI (Masoprokol) • PARP inhibitor (Olaparib) • HDAC (Vorinostat, Romidepsin)
Receptorski antagonisti
ERA (Atrasentan) • retinoid X receptor (Beksaroten) • seks steroid (Testolakton)
Drugi/negrupisani

M: NEO

tmsp, onco, mrkr

tumr, epon, para

drug (L1i/1e)